Graf Acquisition Corp. IV Completes Business Combination with NKGen Biotech

Graf Acquisition Corp. IV completed its previously announced business combination with NKGen Biotech, Inc., resulting in NKGen becoming a wholly‑owned subsidiary and the combined company listing on Nasdaq under the ticker NKGN. The transaction provides NKGen with access to public markets and capital to accelerate development and commercialization of its autologous, allogeneic and CAR‑NK cell therapy programs.